CANCER:

Gastrointestinal Cancer

No biomarker No biomarker	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 days
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	nivolumab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 days
FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval Precision Oncology News - 1 week
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval Precision Oncology News - 1 week
EGFR overexpression EGFR overexpression	Hepatocellular Cancer HCC	gefitinib + lenvatinib Sensitive: C3 – Early Trials Nature - 1 week
GATA6 underexpression GATA6 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Resistant: C3 – Early Trials Sci Rep - 1 week
KRAS G12V KRAS G12V	Colorectal Cancer CRC	FOLFOX Resistant: C3 – Early Trials Sci Rep - 2 weeks
KRAS G12D KRAS G12D	Colorectal Cancer CRC	FOLFOX Resistant: C3 – Early Trials Sci Rep - 2 weeks
KRAS mutation + ATM mutation KRAS mutation + ATM mutation	Rectal Cancer Rectal Cancer	bevacizumab Sensitive: C4 – Case Studies Onco Targets Ther - 2 weeks
MTA2 expression MTA2 expression	Gastric Cancer Gastric Cancer	olaparib Sensitive: D – Preclinical Transl Oncol - 2 weeks
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	nivolumab + ipilimumab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 4 weeks
HER-2 Negative + PD-L1 expression HER-2 Negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - 4 weeks
PD-L1 expression PD-L1 expression	Esophageal Cancer Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - 4 weeks
No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	CEND-1 Sensitive: B - Late Trials Cend Therapeutics Press Release - 4 weeks
MSI-H/dMMR + KRAS Mutation MSI-H/dMMR + KRAS Mutation	Colorectal Cancer CRC	nivolumab + ipilimumab Sensitive: C3 – Early Trials ESMO-GI 2021 - 4 weeks
MSI-H/dMMR + BRAF Mutation MSI-H/dMMR + BRAF Mutation	Colorectal Cancer CRC	nivolumab + ipilimumab Sensitive: C3 – Early Trials ESMO-GI 2021 - 4 weeks
HER-2 positive HER-2 positive	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	trastuzumab + ramucirumab + ALX148 Sensitive: C3 – Early Trials ESMO-GI 2021 - 4 weeks
HER-2 positive HER-2 positive	Gastric Cancer Gastric Cancer	trastuzumab + ramucirumab + ALX148 Sensitive: C3 – Early Trials ESMO-GI 2021 - 4 weeks
ANGPT2-H ANGPT2-H	Colorectal Cancer CRC	regorafenib Sensitive: C3 – Early Trials ESMO-GI 2021 - 4 weeks
KRAS G12C KRAS G12C	Colorectal Cancer CRC	bevacizumab Resistant: C3 – Early Trials ESMO-GI 2021 - 4 weeks
MSI-H/dMMR MSI-H/dMMR	Gastrointestinal Cancer Gastrointestinal Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO-GI 2021 - 4 weeks
MSI-H/dMMR + NTRK3 fusion MSI-H/dMMR + NTRK3 fusion	Colorectal Cancer CRC	larotrectinib Sensitive: C3 – Early Trials ESMO-GI 2021 - 4 weeks
MSI-H/dMMR + NTRK2 fusion MSI-H/dMMR + NTRK2 fusion	Colorectal Cancer CRC	larotrectinib Sensitive: C3 – Early Trials ESMO-GI 2021 - 4 weeks
MSI-H/dMMR + NTRK1 fusion MSI-H/dMMR + NTRK1 fusion	Colorectal Cancer CRC	larotrectinib Sensitive: C3 – Early Trials ESMO-GI 2021 - 4 weeks
PD-L1 expression PD-L1 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab + trametinib Sensitive: C3 – Early Trials Lancet Oncol - 4 weeks
HER-2 S310F + HER-2 amplification HER-2 S310F + HER-2 amplification	Colorectal Cancer CRC	fam-trastuzumab deruxtecan-nxki Resistant: C4 – Case Studies J Natl Compr Canc Netw - 4 weeks
HER-2 S310F + HER-2 amplification HER-2 S310F + HER-2 amplification	Colorectal Cancer CRC	trastuzumab + lapatinib Sensitive: C4 – Case Studies J Natl Compr Canc Netw - 4 weeks
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	ribociclib + alpelisib Sensitive: D – Preclinical ESMO-GI 2021 - 4 weeks
KRAS mutation KRAS mutation	Colorectal Cancer CRC	ribociclib + alpelisib Sensitive: D – Preclinical ESMO-GI 2021 - 4 weeks
HER-2 positive HER-2 positive	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval
No biomarker No biomarker	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Gastric Cancer Gastric Cancer	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Gastric Adenocarcinoma Gastric Adenocarcinoma	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
No biomarker No biomarker	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
HER-2 positive HER-2 positive	Gastric Cancer Gastric Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
HER-2 positive HER-2 positive	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
BRCA2 mutation BRCA2 mutation	Pancreatic Cancer Pancreatic Cancer	olaparib Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	bevacizumab + atezolizumab Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	olaparib Sensitive: A1 - Approval
FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Gastric Cancer Gastric Cancer	TPF Sensitive: A1 - Approval
No biomarker No biomarker	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	TPF Sensitive: A1 - Approval
HER-2 positive HER-2 positive	Gastric Cancer Gastric Cancer	pembrolizumab + trastuzumab Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Colorectal Cancer CRC	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Colorectal Cancer CRC	cetuximab + encorafenib Sensitive: A1 - Approval
No biomarker No biomarker	Colon Cancer Colon Cancer	capecitabine Sensitive: A1 - Approval
No biomarker No biomarker	Rectal Cancer Rectal Cancer	FOLFIRI Sensitive: A1 - Approval
No biomarker No biomarker	Colon Cancer Colon Cancer	5-fluorouracil + irinotecan Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	bevacizumab Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Gastric Cancer Gastric Cancer	trastuzumab Sensitive: A1 - Approval
No biomarker No biomarker	Esophageal Cancer Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval
HER-2 positive HER-2 positive	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Gastric Cancer Gastric Cancer	Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 positive HER-2 positive	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Gastric Cancer Gastric Cancer	Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 positive HER-2 positive	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Gastric Cancer Gastric Cancer	Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 positive HER-2 positive	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Gastric Cancer Gastric Cancer	Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 positive HER-2 positive	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Gastric Cancer Gastric Cancer	Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Rectal Cancer Rectal Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Colon Cancer Colon Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Colon Cancer Colon Cancer	Zirabev (bevacizumab biosimilar) Resistant: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	trifluridine/tipiracil Sensitive: A1 - Approval
No biomarker No biomarker	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	trifluridine/tipiracil Sensitive: A1 - Approval
No biomarker No biomarker	Gastric Cancer Gastric Cancer	trifluridine/tipiracil Sensitive: A1 - Approval
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval
No biomarker No biomarker	Gastric Cancer Gastric Cancer	ramucirumab Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	cabozantinib tablet Sensitive: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	ziv-aflibercept IV Sensitive: A1 - Approval
No biomarker No biomarker	Gastric Cancer Gastric Cancer	capecitabine Sensitive: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	capecitabine Sensitive: A1 - Approval
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	erlotinib Sensitive: A1 - Approval
EGFR expression EGFR expression	Colorectal Cancer CRC	cetuximab Sensitive: A1 - Approval
KRAS Q61 KRAS Q61	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	ramucirumab Sensitive: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	panitumumab Sensitive: A1 - Approval
KRAS A146 KRAS A146	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
No biomarker No biomarker	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	ramucirumab Sensitive: A1 - Approval
HER-2 positive HER-2 positive	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Rectal Cancer Rectal Cancer	irinotecan Sensitive: A1 - Approval
No biomarker No biomarker	Colon Cancer Colon Cancer	irinotecan Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval
AFP elevation AFP elevation	Hepatocellular Cancer HCC	ramucirumab Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	regorafenib Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	lenvatinib Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	sorafenib Sensitive: A1 - Approval
KRAS G13 KRAS G13	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
KRAS G12 KRAS G12	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	nivolumab Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Gastric Cancer Gastric Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	regorafenib Sensitive: A1 - Approval
KRAS K117 KRAS K117	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
KRAS A59 KRAS A59	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	nivolumab + ipilimumab Sensitive: A1 - Approval
HER-2 positive HER-2 positive	Gastric Cancer Gastric Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
KRAS G12S KRAS G12S	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS Q61 NRAS Q61	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
NRAS Q61 NRAS Q61	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS G13 NRAS G13	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS G13 NRAS G13	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
NRAS G12 NRAS G12	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS G12 NRAS G12	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
NRAS A146 NRAS A146	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
NRAS A146 NRAS A146	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
KRAS G13 KRAS G13	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
KRAS G61 KRAS G61	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
KRAS A146 KRAS A146	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS H117 NRAS H117	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
NRAS H117 NRAS H117	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS A59 NRAS A59	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval

Gastrointestinal Cancer

Associations(2264)

Associations
(2264)